These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26941049)

  • 1. Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario.
    Dos Santos Vidal R; Hawrysh A; Walia JS; Davey S; Feilotter H
    J Mol Diagn; 2016 May; 18(3):362-369. PubMed ID: 26941049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
    Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
    Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.
    Azzollini J; Scuvera G; Bruno E; Pasanisi P; Zaffaroni D; Calvello M; Pasini B; Ripamonti CB; Colombo M; Pensotti V; Radice P; Peissel B; Manoukian S
    Eur J Intern Med; 2016 Jul; 32():65-71. PubMed ID: 27062684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
    Yang S; Axilbund JE; O'Leary E; Michalski ST; Evans R; Lincoln SE; Esplin ED; Nussbaum RL
    Ann Surg Oncol; 2018 Oct; 25(10):2925-2931. PubMed ID: 29998407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement.
    Am Fam Physician; 2020 Feb; 101(4):233-238. PubMed ID: 32053325
    [No Abstract]   [Full Text] [Related]  

  • 8. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.
    Stuckey AR; Onstad MA
    Am J Obstet Gynecol; 2015 Aug; 213(2):161-5. PubMed ID: 25747548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical aspects of genetic counseling in breast cancer: lights and shadows.
    Christinat A; Pagani O
    Breast; 2013 Aug; 22(4):375-82. PubMed ID: 23673076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
    Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
    Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
    Konstantopoulou I; Tsitlaidou M; Fostira F; Pertesi M; Stavropoulou AV; Triantafyllidou O; Tsotra E; Tsiftsoglou AP; Tsionou C; Droufakou S; Dimitrakakis C; Fountzilas G; Yannoukakos D
    Clin Genet; 2014 Jan; 85(1):36-42. PubMed ID: 24010542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond BRCA1 and BRCA2.
    King-Spohn K; Pilarski R
    Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.